Source-grounded facts extracted from Quince Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Quince Therapeutics, Inc. shareholders approved Adjournment of Annual Meeting to permit further solicitation and vote of proxies if necessary at the 2026-06-11 meeting.
“The Company’s stockholders approved the adjournment or postponement of the Annual Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in favor of the foregoing proposals.”
Quince Therapeutics, Inc. shareholders approved Advisory approval of compensation of named executive officers at the 2026-06-11 meeting.
“The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the proxy statement.”
Quince Therapeutics, Inc. shareholders approved Ratification of Selection of Independent Registered Accounting Firm BDO USA, P.C. for fiscal year ending December 31, 2026 at the 2026-06-11 meeting.
“The Company’s stockholders ratified the selection of BDO USA, P.C. as the Company’s independent registered accounting firm for the fiscal year ending December 31, 2026.”
Quince Therapeutics, Inc. shareholders approved Approval of Amendment to the Certificate of Incorporation to Effect a Reverse Stock Split at a ratio ranging from one-for-ten to one-for-one hundred at the 2026-06-11 meeting.
“The Company’s stockholders approved the amendment to the Company’s amended and restated certificate of incorporation to effect a reverse stock split of the Company’s issued and outstanding common stock at a ratio ranging from one-for-ten (1-for-10) to one-for-one hundred (1-for-100) with such reverse stock split to be effected at such time and date, if at all, as determined by the Company’s board of directors in its sole discretion.”
Quince Therapeutics, Inc. shareholders approved Election of one Class I director to serve until the 2029 annual meeting at the 2026-06-11 meeting.
“The Company’s stockholders approved the election of one Class I director to the Board of Directors to serve until the 2029 annual meeting of stockholders and until her successor is duly elected and qualified or until her earlier death, resignation, disqualification or removal.”
Quince Therapeutics, Inc.: Filed Certificate of Designation creating Series C Preferred Stock (effective 2026-05-18).
“On May 18, 2026, the Company filed with the Secretary of State of the State of Delaware a Certificate of Designation of Preferences, Rights and Limitations of the Series C Preferred Stock (the " Certificate of Designation ") in connection with the Acquisition and the Financing referenced in Item 1.01 above.”
Quince Therapeutics, Inc. completed an acquisition involving Orphai Therapeutics, LLC and Orphai Holdings Therapeutics, Inc. (closed 2026-05-18).
“On May 18, 2026, the Company completed its acquisition of the Orphai Entities.”
Brigette Roberts was appointed as Chief of Corporate Affairs at Quince Therapeutics, Inc..
“Dr. Roberts was also appointed as the Chief of Corporate Affairs of the Company.”
Brigette Roberts was appointed as Director at Quince Therapeutics, Inc..
“Brigette Roberts, M.D., was appointed to the Board as a Class III director.”
Quince Therapeutics, Inc. issued common stock.
“every ten (10) shares of the Company’s issued and outstanding common stock will be automatically combined and converted into one (1) issued and outstanding share of common stock”
Quince Therapeutics, Inc.: Filed Certificate of Amendment to effect a 1-for-10 reverse stock split of common stock, effective April 10, 2026 (effective 2026-04-10).
“on April 9, 2026, the Company filed the Certificate of Amendment with the Secretary of State of the State of Delaware, which will be effective at 11:59 pm Eastern Time on April 10, 2026.”
Quince Therapeutics, Inc. terminated Finance Contract with European Investment Bank (EIB) valued at EUR 4,800,000, or approximately $5.5 million (effective 2026-03-27).
“As previously disclosed, Quince Therapeutics, Inc. (the “Company”), Quince Therapeutics S.p.A. (the “Borrower”), the European Investment Bank (the “EIB”) and other parties named therein previously entered into a finance contract dated July 24, 2020 (as amended and restated, the “Finance Contract”) and a related guarantee agreement in connection with the Finance Contract (the “Guarantee Agreement,” together with the Finance Contract, the “Finance Documents”). On March 27, 2026, the Company agreed to pay, on the Borrower’s behalf, EUR 4,800,000, or approximately $5.5 million, to the EIB in full settlement of the Borrower’s obligations under the Finance Documents. As a result of the Company’s payment of such amount, the Company’s and the Borrower’s obligations under the finance documents were deemed satisfied.”
Quince Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
“March 16, 2026, Quince Therapeutics, Inc. (the “Company”) received a notice (the “Bid Price Notice”) from the Nasdaq Listing Qualifications department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the closing bid price of the Company’s common stock for the last 30 consecutive business days had closed below the minimum $1.00 per share required for continued listing under Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The Company has a period of 180 calendar days, or until September 14, 2026 (the “Compliance Date”), to regain compliance with the Minimum Bid”
Rajiv Patni was appointed as director at Quince Therapeutics, Inc..
“the board of directors (the “ Board ”) of Quince Therapeutics, Inc. (the “ Company ”) appointed Rajiv Patni to serve as a director of the Company, effective as of February 15, 2024.”
Quince Therapeutics, Inc. terminated License Agreement with Purdue Research Foundation valued at License terminated; 35% of payments to Company if PRF licenses to certain third parties (effective 2023-10-31).
“On December 22, 2023, the Board of Directors of Quince Therapeutics, Inc. (the “Company”), following its prior decision to discontinue internal development of NOV004, approved that certain Mutual Termination of License Agreement (the “Termination Agreement”) by and between the Company and Purdue Research Foundation (“PRF”), to terminate the License Agreement dated June 3, 2020, as amended on March 17, 2022, July 22, 2022, and June 23, 2023 (the “License Agreement”).”
Quince Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
“December 4, 2023, Quince Therapeutics, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, based on the closing bid price of the Company’s common stock, par value $0.001 per share (the “Common Stock”), for the last 30 consecutive trading days, the Company no longer complies with the minimum bid price requirement for continued listing on The Nasdaq Global Select Market. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per share (t”
Brendan Hannah was appointed as Chief Operating Officer at Quince Therapeutics, Inc..
“On October 24, 2023, the Board of Directors of Quince Therapeutics, Inc. (the “Company”) appointed Brendan Hannah to the position of Chief Operating Officer of the Company.”
Quince Therapeutics, Inc. completed an acquisition involving EryDel S.p.A for 6,525,315 shares of common stock (closed 2023-10-20).
“company solely in its capacity as the representative, agent and attorney-in-fact of the EryDel Shareholders. Pursuant to the terms of the Purchase Agreement, the Company issued 6,525,315 shares of common stock of the Company to the EryDel Shareholders, resulting in the EryDel Shareholders owning approximately 15.2% of the outstanding common stock of the Company.”
Quince Therapeutics, Inc. incurred credit facility of EUR 30,000,000 unsecured credit facility with European Investment Bank at 9.00% per annum maturing August 11, 2026.
“the “Quince Parties”), have agreed to guarantee the obligations of EryDel S.p.A, a company with shares incorporated under the laws of Italy (“EryDel”), in respect of a EUR 30,000,000 unsecured credit facility (the “EIB Facility”) evidenced by the Finance Contract, dated as of July 24, 2020 (the “Existing Finance Contract” and, as amended by the Amendment, the”
Quince Therapeutics, Inc. entered into Finance Contract with European Investment Bank valued at EUR 30,000,000 (effective 2023-10-20).
“the Finance Contract, dated as of July 24, 2020 (the “Existing Finance Contract” and, as amended by the Amendment, the “Amended Finance Contract”), by and between EryDel, as borrower, and the European Investment Bank, as lender (the “Lender”), by entering into (i) an Accession, Amendment and Restatement Agreement, dated as of October 20, 2023 (the “Amendment”), which amends and restates the Existing Finance Contract and joins each Quince Party thereto as a guarantor of the obligations of EryDel thereunder, and (ii) an Autonomous First Demand Guarantee ( Garanzia Autonoma a Prima Richiesta ) by each Quince Party respectively in favor of the Lender (collectively, the “Guarantees”).”
Luca Benatti was appointed as Director at Quince Therapeutics, Inc..
“appointed Luca Benatti to serve as a director of the Company, effective as of the first business day following the closing of the EryDel Acquisition.”
Quince Therapeutics, Inc. incurred loan of up to $1.0 million with Erydel S.p.A. at 5.07% per annum maturing July 1, 2024.
“shares (società per azioni) incorporated under the laws of Italy (“EryDel”) (the “Promissory Note”), pursuant to which EryDel Italy promised to make advances to EryDel of up to $1.0 million. The Company previously entered into a Stock Purchase Agreement, dated as of July 21, 2023, by and among the Company, EryDel, and the other parties thereto. Under the terms of”
Charles S. Ryan was appointed as President at Quince Therapeutics, Inc..
“On August 30, 2023, the Board of Directors of the Company approved the appointment of Charles S. Ryan, Ph.D., as the President of the Company, effective as of September 1, 2023.”
Karen Smith departed as Chief Medical Officer at Quince Therapeutics, Inc..
“On July 24, 2023, Quince Therapeutics, Inc. (the “Company”) announced the departure of Karen Smith, M.D., Ph.D., the Company’s Chief Medical Officer, effective as of September 1, 2023”
Quince Therapeutics, Inc. incurred loan of $13 million (€10 million in principal) with European Investment Bank (EIB).
“In connection with and contingent upon the consummation of the EryDel Acquisition, the Company will assume EryDel’s $13 million (€10 million in principal) European Investment Bank (EIB) loan with scheduled payments beginning in the second half of 2026.”
Quince Therapeutics, Inc. entered into Stock Purchase Agreement with EryDel S.p.A. and the EryDel Shareholders valued at up to $485,000,000 in potential cash payments (effective 2023-07-21).
“On July 21, 2023 (the “Agreement Date”), Quince Therapeutics, Inc., a Delaware corporation (the “Company”), EryDel Italy, Inc., a Delaware corporation and wholly owned indirect subsidiary of the Company, EryDel S.p.A, a company with shares incorporated under the laws of Italy, (“EryDel”), holders of EryDel capital stock and the managers of EryDel (the “EryDel Shareholders”) and Shareholder Representative Services LLC, a Colorado limited liability company solely in its capacity as the representative, agent and attorney-in-fact of the EryDel Shareholders, entered into a Stock Purchase Agreement (the “Purchase Agreement”), pursuant to which, and subject to the terms and conditions set forth in the Purchase Agreement, the Company will indirectly acquire all of the outstanding equity interests of EryDel (the “EryDel Acquisition”).”
Karen Smith departed as Chief Medical Officer at Quince Therapeutics, Inc..
“On July 24, 2023, the Company announced that Karen Smith, Chief Medical Officer of the Company, would be leaving the Company, effective September 1, 2023.”
Luca Benatti was appointed as director at Quince Therapeutics, Inc..
“On July 21, 2023, the Company Board of Directors approved the appointment of Luca Benatti to serve as a director of the Company, contingent and effective upon the closing of the EryDel Acquisition.”
Quince Therapeutics, Inc. shareholders approved Advisory approval of the compensation of the Company's named executive officers at the 2023-05-24 meeting.
“The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers.”
Quince Therapeutics, Inc. shareholders approved Ratification of Selection of Independent Registered Accounting Firm BDO USA, LLP at the 2023-05-24 meeting.
“The Company’s stockholders ratified the selection of BDO USA, LLP as the Company’s independent registered accounting firm for the fiscal year ending December 31, 2023.”
Quince Therapeutics, Inc. shareholders approved Approval of Amendment to the Certificate of Incorporation to Effect a Reverse Stock Split at a ratio of one-for-ten at the 2023-05-24 meeting.
“The Company’s stockholders approved the amendment to the Company’s amended and restated certificate of incorporation to effect a reverse stock split of the issued and outstanding common stock at a ratio of one-for-ten.”
Quince Therapeutics, Inc. shareholders approved Election of two Class I directors at the 2023-05-24 meeting.
“The Company’s stockholders approved the election of two Class I directors to the Board of Directors for three year terms or until their respective successors are duly elected and qualified or until their earlier death, resignation, disqualification or removal.”
Quince Therapeutics, Inc.: Board adopted a limited duration stockholder rights plan, declaring a dividend of one preferred share purchase right per common share, effective immediately, expiring April 5, 2024 (effective 2023-04-05).
“its Board of Directors (the “Board”) unanimously approved the adoption of a limited duration stockholder rights plan (the “Rights Plan”) and declared a dividend distribution of one preferred share purchase right on each outstanding share of Quince’s common stock.”
Philip Low resigned as Director at Quince Therapeutics, Inc..
“On March 27, 2023, Philip Low. Ph.D., a member of the Board of Directors (the “Board”) of Quince Therapeutics, Inc. (the “Company”), tendered his resignation from the Board, effective immediately”
Brendan Hannah was appointed as principal financial officer and principal accounting officer at Quince Therapeutics, Inc..
“On March 3, 2023, the Board of Directors of the Company appointed Brendan Hannah, Chief Business Officer of the Company, as the Company’s principal financial officer and principal accounting officer, effective as of March 16, 2023.”
Ted Monohon resigned as Chief Accounting Officer and Vice President of Finance at Quince Therapeutics, Inc..
“On March 1, 2023, Ted Monohon informed Quince Therapeutics, Inc. (the “ Company ”) of his intention to resign from his position as the Chief Accounting Officer and Vice President of Finance, including as the principal financial officer and principal accounting officer, effective as of March 16, 2023.”
Quince Therapeutics, Inc. reported preliminary financial results for the fourth quarter and year ended December 31, 2022.
“The Company also reported on a preliminary and unaudited basis its estimated cash, cash equivalents, and marketable securities of approximately $94 million as of December 31, 2022.”
Quince Therapeutics, Inc. announced a restructuring with charges of approximately $0.6 million to $0.8 million (approximately 47%).
“share-based compensation and any one-time costs related to strategic actions). In connection with the Plan, the Company estimates that it will incur expenses of approximately $0.6 million to $0.8 million, substantially all of which will be cash expenditures and other costs relating to the Plan through August 2023. The Company may incur other charges, including”
Quince Therapeutics, Inc. entered into Asset Purchase Agreement with Lighthouse Pharmaceuticals, Inc. valued at up to $150 million (effective 2023-01-27).
“On January 27, 2023, Quince Therapeutics, Inc. (the “ Company ”) entered into an Asset Purchase Agreement (the “ Purchase Agreement ”) with Lighthouse Pharmaceuticals, Inc. (“ Purchaser ”) for the sale of its legacy small molecule protease inhibitor portfolio for all uses and indications throughout the world”
Quince Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
“December 13, 2022, Quince Therapeutics, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, based on the closing bid price of the Company’s common stock, par value $0.001 per share (the “Common Stock”), for the last 30 consecutive trading days, the Company no longer complies with the minimum bid price requirement for continued listing on The Nasdaq Global Select Market. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per share (”
Marwan Sabbagh resigned as Member of the Board of Directors at Quince Therapeutics, Inc..
“On September 28, 2022, Marwan Sabbagh, M.D., a member of the Board of Directors (the “Board”) of Quince Therapeutics, Inc. (the “Company”), tendered his resignation from the Board, effective as of September 30, 2022 (the “Departure Date”).”
Leslie Holsinger resigned as Executive Vice President of Research and Development at Quince Therapeutics, Inc..
“On July 20, 2022, the Company entered into a transition agreement (the “Separation Agreement”) with Leslie Holsinger, Ph.D., relating to her resignation from her role as the Executive Vice President of Research and Development of the Company, effective as of July 31, 2022 (the “Departure Date”).”
June Bray was appointed as Class III director at Quince Therapeutics, Inc..
“On June 9, 2022, upon recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed June Bray to serve as a Class III director of the Company, effective immediately”
Christopher Lowe resigned as Chief Operating Officer at Quince Therapeutics, Inc..
“Mr. Lowe has also resigned from his roles as the Chief Financial Officer and Chief Operating Officer of the Company, effective as of June 10, 2022 (the “Departure Date”).”
Christopher Lowe resigned as Chief Financial Officer at Quince Therapeutics, Inc..
“Mr. Lowe has also resigned from his roles as the Chief Financial Officer and Chief Operating Officer of the Company, effective as of June 10, 2022 (the “Departure Date”).”
Christopher Lowe resigned as member of the Board of Directors at Quince Therapeutics, Inc..
“On June 8, 2022, Christopher Lowe, the Chief Financial Officer, Chief Operating Officer and a member of the Board of Directors (the “Board”) of the Company, resigned as a member of the Board, effective immediately.”
Caryn McDowell departed as Chief Legal and Administrative Officer and Corporate Secretary at Quince Therapeutics, Inc..
“On May 20, 2022, the Company announced the departure of Caryn McDowell, the Company’s Chief Legal and Administrative Officer and Corporate Secretary, effective as of July 8, 2022 (the “Departure Date”).”
Dirk Thye was appointed as Chief Executive Officer at Quince Therapeutics, Inc..
“the appointment of Dirk Thye, M.D. as the Chief Executive Officer of the Company and as principal executive officer and a Class II director of the Company”
Michael Detke departed as Chief Medical Officer at Quince Therapeutics, Inc..
“Effective May 2, 2022 (the “Departure Date”), Michael Detke, M.D., Ph.D., the Company’s Chief Medical Officer, will step down from his position as the Chief Medical Officer.”
Marwan Noel Sabbagh was appointed as Director at Quince Therapeutics, Inc..
“On March 14, 2022, upon recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Cortexyme, Inc. (the “Company”), the Board appointed Marwan Noel Sabbagh, M.D., to serve as a Class II director of the Company, effective immediately”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.